Improving & Enhancing
Antibody Efficacy
By Converting Antibodies Into Bispecifics

Imunexus' technology facilitates rapid, cost-effective, lower risk, generation of effective therapeutics by converting existing monoclonal antibodies into multispecifics with additional therapeutic utility.

Our technology will generate a number of potential products for the treatment of a number of cancers, autoimmune and other serious diseases.

Our Focus
Imunexus is focusing on two lead products that address serious disease indications.
How the Technology Works
Imunexus 'Turbo Charges' existing monoclonal antibodies by combining existing monoclonal antibodies with the Company's proprietary imunexin
Latest News
Technology that "Turbo Charges"
existing antibody drugs or other proteins.
Imunexus 'Turbo Charges' existing monoclonal antibodies by combining the existing monoclonal antibodies with the Company's proprietary imunexinTM modules.
Existing monoclonal antibodies include marketed antibodies, clinical stage antibodies, and advanced preclinical antibodies.
Imunexus Team
Philippa Lewis
Chairperson
John Gaffney
Non Executive Director
Don Brumley
Non-Executive Director
Dr George Kopsidas
Chief Scientific Officer
Christopher Elliot
Chief Financial Officer and Company Secretary
Paul Field
Business Advisor
Dr Simon Green
Scientific Advisor